key: cord-0938286-vn4y6cfy
authors: Sperotto, Alessandra; Candoni, Anna; Petruzzellis, Giuseppe; Mullai, Rikard; Patriarca, Francesca; Tascini, Carlo; Fanin, Renato
title: Screening procedure for SARS‐CoV‐2 infection combining triage, nasopharyngeal swab and serological test in allogeneic stem cell transplantation recipients undergoing outpatient posttransplant follow‐up
date: 2020-10-30
journal: J Med Virol
DOI: 10.1002/jmv.26586
sha: 98801dbca8ea53412b622290c26b5f6c0313a7f7
doc_id: 938286
cord_uid: vn4y6cfy

In Italy, the first Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) positive patient was identified on February 21, 2020 and as of June 30, 2020 more than 240.000 people have been diagnosed and over 34.000 have died. This article is protected by copyright. All rights reserved.

Screening procedure for SARS-CoV-2 infection combining triage, nasopharyngeal swab and serological test in allogeneic stem cell transplantation recipients undergoing outpatient posttransplant follow-up

To the Editor, In Italy, the first severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive patient was identified on February 21, 2020 and as of June 30, 2020 more than 240,000 people have been diagnosed and over 34,000 have died. 1 In our country, the overall incidence of symptomatic SARS-CoV-2 infection, called coronavirus disease 2019 (COVID-19), is 396 cases every 1000 inhabitants. Our hematologic center is located in the northerneast of Italy, where this data decrease to 269 out of 1000 inhabitants (http://covid19.intelworks.io/). However, despite the availability of data on prevalence of symptomatic SARS-CoV-2 infection (COVID-19) in the general population the data on real number of asymptomatic SARS-CoV-2 carriers are unavailable. [1] [2] [3] [4] When the first patient with COVID-19 was diagnosed in our Hospital, we were faced with the dilemma of how to counteract, in everyday clinical practice, the spread of symptomatic and asymptomatic SARS-CoV-2 infection in our allogeneic-stem cell transplant (Allo-SCT) recipients undergoing post-SCT outpatient monitoring at our day hospital ward (DH). 4 To reduce the risk of infection spread and to minimize clinical staff exposure, Allo-SCT patients admitted to our DH strictly followed the prevention practices as recommended and published by the European group for blood and marrow transplantation (EBMT), including hygiene procedures, surgical mask and social distancing. 5 Unless necessary, caregivers were not admitted to the DH. 5 Moreover, a quantitative serological test (euroimmune anti-SARS-CoV-2 Elisa) was performed, resulting negative (IgG and IgM antibodies). So that, the infectious disease team concluded for a false positive rapid serological test.

As a conclusive result of this stringent monitoring, we found that our Allo-SCT tested population was SARS-CoV-2 free (neither asymptomatic nor symptomatic cases).

Although we found no positive cases, we believe our screening experience worthy of reporting for different reasons: it represents a viable monitoring option in clinical practice in a specific setting of patients (Allo-SCT) at high risk of developing a severe SARS-CoV-2 infection. 2, 5, 6 Moreover, the concomitant evaluation of the two available tests (NPS and rapid serological test) might improve the detection of SARS-CoV-2 infection prevalence (we underline that the sensibility of NPS alone is around 70%) and it might be useful to verify the efficacy of the prevention practices that have been adopted according to the EBMT recommendations. 5 Last but not least, the absence of detection during the pandemic period (combining two different tests), of positive SARS-CoV-2 cases in our Allo-SCT population, represented for our patients, for their family members and also for the healthcare workers, a feeling of security. We would also underline the complete compliance of all the 70 patients for performing both the NPS and the serological test.

We are aware that, up to now, it is not completely clear which is the sensitivity and specificity of the rapid, qualitative serological SARS-CoV-2 diagnostic tests in a setting of immunocompromised patients in which a reduction of immune response and consequently of seroconversion is expected. [10] [11] [12] However, with this concern, our experience suggests that a vulnerable Allo-SCT population, if screened with a combined approach and instructed properly, might avoid the diffusion of SARS-CoV-2 infection. 5 In conclusion, in Allo-SCT an active screening for SARS-CoV-2 infection could be performed with a combined approach, including triage procedure, molecular (RT-PCR from NPS) and serological tests.

This approach could be useful to define the prevalence of SARS-CoV-2 infection (including symptomatic and asymptomatic cases) in the context of a vulnerable population and it should be taken into account as a useful tool especially in the case of a regrowth of SARS-CoV-2 virus spread.

The authors declare that there are no conflict of interests.

Anna Candoni, Alessandra Sperotto, and Giuseppe Petruzzellis: data collection, data analysis and drafting the manuscript. Renato Fanin: data collection. Francesca Patriarca: support in study design. Carlo

Tascini and Renato Fanin: study design and manuscript revision.

The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions. 

Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy

COVID-19 in persons with haematologic cancers

Asymptomatic cases with SARS-CoV-2 infection

Asymptomatic transmission, the Achilles' heel of current strategies to control COVID-19

The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy

Hematology and oncology clinical care during the coronavirus disease 2019 pandemic

Detection of SARS-CoV-2 in different types of clinical specimens

False negative test for SARS-CoV-2 infection-challenges and implications

Interpreting a COVID-19 test result

Developement and clinical application of rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis

A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version)

Interpreting diagnostic tests for SARS-CoV-2